Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.58 |
| ▸ | CTSK | P43235 | 8/20 | 0.55 |
| ▸ | CTSS | P25774 | 4/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | CASP7 | P55210 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 2/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21110017 | 0.91 | CTSK (0.63) | CTSLCTSKCTSSCTSB | |
| SCHEMBL21110027 | 0.90 | CTSK (0.54) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL19345781 | 0.90 | CTSK (0.54) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL21110555 | 0.90 | CTSK (0.54) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL21109818 | 0.89 | CTSK (0.49) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL19345776 | 0.88 | CTSK (0.55) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL21109280 | 0.88 | CTSK (0.55) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL19345743 | 0.88 | CTSK (0.55) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL21110564 | 0.87 | HLA-DRB1 (0.55) | CTSLCTSKCTSSCTSBCASP1 | |
| SCHEMBL21109625 | 0.87 | CTSK (0.50) | CTSLCTSKCTSSCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | CTSL 1363/4885CTSK 566/4885CTSS 905/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | CTSL 1363/4885CTSK 566/4885CTSS 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.